17,261 trials
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 — 12.7; 15.9; 15.9; 9.5 percentage of participants — p=0.598
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 2; 2; 12; 42 Participants
Metastatic Breast Cancer
Primary: The Safety of dHER2+AS15 ASCI When Administered in Combination With Lapatinib Measured by Occurrence of Severe Toxicities (According to CTCAE, Version 3.0) — 0…
Dermatitis, Atopic
Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…
Dermatitis, Allergic Contact
Primary: Number of Participants With Positive Reaction Scores Based Upon ICDRG Scoring Scale: Regimen 1 — 5; 9 Participants
Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Urologic Neoplasms
Primary: Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) — 44; 51.7 Percentage of Participants
Cystinuria
Primary: Change in Cystine Capacity From Baseline — -63.6; 76; 53.4; 103.1 mg/L
Alzheimer's Disease
Primary: Number of Participants Experiencing Diarrhea Caused by Clostridium Difficile — 5 Participants
Primary Ciliary Dyskinesia
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs — 52; 46; 22; 23 Participants
Peanut Hypersensitivity · Food Allergy · Food Hypersensitivity
Primary: Desensitization After 36 Months of Peanut SLIT or Placebo SLIT — 4.9; 2.5 score on a scale — p=0.002
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
Chronic Lymphocytic Leukemia · 17p Deletion · Cancer of the Blood and Bone Marrow
Primary: Overall Response Rate (Main Cohort) — 77.1 percentage of participants — p=<0.001
Metastatic Cholangiocarcinoma · Cholangiocarcinoma · Pancreatic Cancer
Primary: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) — 0; 3 Participants
Malaria,Falciparum · Plasmodium Falciparum · Plasmodium Berghei
Primary: Adverse Events in Study Groups Following Exposure to Pb(PfCS@UIS4)-Infected Mosquitoes [Safety] — 0; 3; 10; 9 numbers of adverse events
Major Depressive Disorder
Primary: The GRID-Hamilton Depression Rating Scale (GRID-HAMD) — 22.9; 22.5; NA; 23.8 units on a scale